In this episode I sit down with Kim Witczak, a consumer advocate and FDA advisor, and Dr. Matt Johnson from Johns Hopkins University, to dive into the FDA’s recent decision to reject MDMA-assisted therapy for PTSD. We explore the pressing concerns around the safety and ethics of MDMA therapy, including issues like inadequate cardiovascular monitoring, the underreporting of adverse events, and allegations of misconduct during clinical trials.

Kim shares her cautious perspective on the risks, while Matt highlights the strong evidence supporting MDMA’s effectiveness and questions whether psychedelics are being unfairly held to a higher standard. We also discuss the challenges of maintaining a proper blind in psychedelic research, the lack of diversity in clinical trials, and what all this means for the future of PTSD treatment. Join us for a deep and nuanced conversation on the crossroads of psychedelic science, ethics, and regulation.

Receive Exclusive Episodes & Q&A Content by joining our Substack Community: https://www.illusionconsensus.com/

Kim Witczak

X - https://x.com/woodymatters?lang=en

Website - https://www.woodymatters.com/about

Dr Matt Johnson on X - https://x.com/drug_researcher